Archana Radhakrishnan

Archana Radhakrishnan

Auto-generated profile, based on publicly available information

Archana Radhakrishnan

Department of Internal Medicine University of Michigan Ann Arbor Michigan USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
ARArchana Radhakrishnan
Archana Radhakrishnan
SNSarah A. Nowak
Sarah A. Nowak
APAndrew M. Parker
Andrew M. Parker
KVKala Visvanathan
Kala Visvanathan
CPCraig Evan Pollack
Craig Evan Pollack
Different professional societies and organizations continue to disagree over the optimal time to initiate and discontinue breast cancer screening mammography and the optimal screening interval. In October 2015, the American Cancer Society (ACS) revised its guidelines, encouraging personalized screening decisions for women ages 40 to 44 years followed by annual screening starting at age 45 years and biennial screening for women 55 years or older.1 The US Preventive Services Task Force (USPSTF) reissued its recommendations in January 2016 recommending personalized screening decisions for women ages 40 to 49 years followed by biennial mammograms for women ages 50 to 74 years.2 The American Congress of Obstetricians and Gynecologists (ACOG) recommends yearly mammograms for women 40 years or older.3 With physician recommendations the most important determinant for patients obtaining screening,4 we investigated physician recommendations in light of recent guideline changes in a national sample.

1 September 2017 in Medical Care
Verified
Journal Article
Closed access
MWMichelle S. Wong
Michelle S. Wong
DGDavid T. Grande
David T. Grande
NMNandita Mitra
Nandita Mitra
ARArchana Radhakrishnan
Archana Radhakrishnan
CBCharles C. Branas
Charles C. Branas
CPCraig E. Pollack
Craig E. Pollack
Background: Geographic access—the travel burden required to reach medical care—is an important aspect of care. Studies, which typically rely on geographic information system (GIS) calculated travel times, have found some evidence of racial disparities in spatial access to care. However, the validity of these studies depends on the accuracy of travel times by patient race. Objectives: To determine if there are racial differences when comparing patient-reported and GIS-calculated travel times. Research Design: Data came from the Philadelphia Area Prostate Cancer Access Study (P2 Access), a cohort study of men diagnosed with localized prostate cancer. We conducted cross-sectional analysis of 2136 men using multivariable linear mixed-effects models to examine the effect of race on differences in patient-reported and GIS-calculated travel times to urology and radiation oncology cancer providers. Results: Patient-reported travel times were, on an average, longer than GIS-calculated times. For urology practices, median patient-reported travel times were 12.7 minutes longer than GIS-calculated travel times for blacks versus 7.2 minutes longer for whites. After adjusting for potential confounders, including socioeconomic status and car access, the difference was significantly greater for black patients than white patients (2.0 min; 95% confidence interval, 0.58–3.44). Conclusions: GIS-calculated travel time may underestimate access to care, especially for black patients. Future studies that use GIS-calculated travel times to examine racial disparities in spatial access to care might consider including patient-reported travel times and controlling for factors that might affect the accuracy of GIS-calculated travel times.

1 February 2018 in Preventive Medicine
Verified
Journal Article
Closed access
ARArchana Radhakrishnan
Archana Radhakrishnan
SNSarah A. Nowak
Sarah A. Nowak
APAndrew M. Parker
Andrew M. Parker
KVKala Visvanathan
Kala Visvanathan
CPCraig E. Pollack
Craig E. Pollack

20 July 2017 in Ethnicity & Disease
Verified
Journal Article
Open access
PDF file
MWMegan Watson
Megan Watson
DGDavid Grande
David Grande
ARArchana Radhakrishnan
Archana Radhakrishnan
NMNandita Mitra
Nandita Mitra
KWKatelyn R. Ward
Katelyn R. Ward
CPCraig Evan Pollack
Craig Evan Pollack
Objective: This study examines whether socioeconomic status (SES), measured at both the individual and neighborhood levels, is associated with receipt of definitive treatment for localized prostate cancer and whether these associations mediate racial differences in treatment between non-Hispanic White and non-Hispanic Black men. Design: The Philadelphia Area Prostate Cancer Access Study (P2 Access) is a mailed, cross-sectional survey of men sampled from the Pennsylvania Cancer Registry, combined with neighborhood Census data. Setting: Eight counties in southeastern Pennsylvania. Participants: 2,386 men with prostate adenocarcinoma. Main Measures: Receipt of definitive treatment, race, self-reported income, education, employment status, and neighborhood SES. Results: Overall, Black and White men were equally likely to receive definitive treatment. Men living in neighborhoods with higher SES were more likely to receive definitive treatment (OR 1.57, 95%CI 1.01, 2.42). Among men who received definitive treatment, Black men were significantly less likely to receive radical prostatectomy compared with White men (OR .71, 95% CI .52, .98), as were men with some college education compared with those with a high school education or less (OR .66, 95% CI .47, .94). SES does not mediate racial differences in receipt of definitive treatment or the type of definitive treatment received, and associations with income or employment status were not significant. Conclusions: These results stress the importance of examining racial disparities within geographic areas and highlight the unique associations that different measures of SES, particularly neighborhood SES and education, may have with prostate cancer treatment.Ethn Dis. 2017;27(3):201-208; doi:10.18865/ed.27.3.201.

1 February 2019 in Cancer
Verified
Journal Article
Open access
PDF file
LWLauren P. Wallner
Lauren P. Wallner
YLYun Li
Yun Li
MMM. Chandler McLeod
M. Chandler McLeod
JGJoan Gargaro
Joan Gargaro
AKAllison W. Kurian
Allison W. Kurian
SKSteven J. Katz
Steven J. Katz
Background: Treatment decisions for patients with early‐stage breast cancer often involve discussions with multiple oncology providers. However, the extent to which primary care providers (PCPs) are involved in initial treatment decisions remains unknown. Methods: A stratified random sample of PCPs identified by newly diagnosed patients with early‐stage breast cancer from the Georgia and Los Angeles Surveillance, Epidemiology, and End Results registries were surveyed (n = 517; a 61% response rate). PCPs were asked how frequently they discussed surgery, radiation, and chemotherapy options with patients; how comfortable they were with these discussions; whether they had the necessary knowledge to participate in decision making; and what their confidence was in their ability to help (on 5‐item Likert‐type scales). Multivariate logistic regression was used to identify PCP‐reported attitudes associated with more PCP participation in each treatment decision. Results: In this sample, 34% of PCPs reported that they discussed surgery, 23% discussed radiation, and 22% discussed chemotherapy options with their patients. Of those who reported more involvement in surgical decisions, 22% reported that they were not comfortable having a discussion, and 17% did not feel that they had the necessary knowledge to participate in treatment decision making. PCPs who positively appraised their ability to participate were more likely to participate in all 3 decisions (odds ratio [OR] for surgery, 6.01; 95% confidence interval [CI], 4.16‐8.68; OR for radiation, 8.37; 95% CI, 5.16‐13.58; OR for chemotherapy, 6.56; 95% CI, 4.23‐10.17). Conclusions: A third of PCPs reported participating in breast cancer treatment decisions, yet gaps in their knowledge about decision making and in their confidence in their ability to help exist. Efforts to increase PCPs’ knowledge about breast cancer treatment options may be warranted.

20 July 2017 in Cancer
Verified
Journal Article
Closed access
PDF file
CPCraig Evan Pollack
Craig Evan Pollack
KAKatrina A. Armstrong
Katrina A. Armstrong
NMNandita Mitra
Nandita Mitra
XCXinwei Chen
Xinwei Chen
KWKatelyn R. Ward
Katelyn R. Ward
DGDavid T. Grande
David T. Grande